Bioprinted Bladder Cancer Organoids Model System for Prediction of Chemotherapy Response and Drug Screening
Open Access
- 7 July 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (13) , 6082
Abstract
Bladder cancer is the fifth most common cancer in the United States, causing approximately 17,000 deaths annually. Due to its vast genetic and molecular heterogeneity, presentation, prognosis, and therapeutic response vary greatly between individuals. To improve patient outcomes, there is a need for better drug-screening platforms. The genetic heterogeneity of bladder cancer often leads to chemotherapy resistance or low response rates. Moreover, chemotherapies are often contraindicated in patients with select comorbidities. Organoids offer a better option to replicate the tumor microenvironment than traditional 2D cell cultures, improving drug development and personalized therapy. In this study, we bioprinted gelatin-methacrylol (GelMA)-based organoids containing bladder cancer cell lines of different grades to model muscle-invasive bladder cancer. In the organoids, we observed distinct grade-dependent tumor proliferation and progression dynamics. Treatment with standard-of-care chemotherapies revealed a grade-dependent tumor response consistent with in vivo patient data, highlighting the suitability of these organoids for rapid, reliable drug testing. Lastly, we used the organoids to test LCI139, a novel small-molecule inhibitor of PI3K, CDK4/6, and CDK9 designed for the treatment of epithelial cancers, underscoring the potential of our model to evaluate the efficacy of newly developed drugs. The ability to quickly biofabricate reproducible bladder cancer organoids that are adaptable to different tumor grades represents a novel strategy to create an in vitro platform with strong potential to predict treatment outcomes of bladder cancer patients.Keywords
Funding Information
- Department of Urology, Wake Forest Baptist Medical Center
This publication has 47 references indexed in Scilit:
- Exploring the Effectiveness of Sitagliptin to Enhance Cisplatin Chemosensitivity in HTB‐9 Bladder Cancer CellsJournal of Biochemical and Molecular Toxicology, 2025
- Patient‐Derived Bladder Cancer Organoids as a Valuable Tool for Understanding Tumor Biology and Developing Personalized TreatmentAdvanced Science, 2025
- Basic fibroblast growth factor‐loaded methacrylate gelatin hydrogel microspheres for spinal nerve regenerationSmart Medicine, 2023
- Patient-derived organoids as a model for tumor research2022
- Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancerCancer Immunology, Immunotherapy, 2020
- The Tumor Microenvironment of Bladder Cancer2020
- Development of a Colorectal Cancer 3D Micro-tumor Construct Platform From Cell Lines and Patient Tumor Biospecimens for Standard-of-Care and Experimental Drug ScreeningAnnals of Biomedical Engineering, 2019
- Gelatin methacrylate scaffold for bone tissue engineering: The influence of polymer concentrationJournal of Biomedical Materials Research Part A, 2017
- Proteome array identification of bioactive soluble proteins/peptides in Matrigel: relevance to stem cell responsesCytotechnology, 2014
- Identification of multiple active growth factors in basement membrane matrigel suggests caution in interpretation of cellular activity related to extracellular matrix componentsExperimental Cell Research, 1992